A Phase 2, Single Arm Study Investigating the Use of Chidamide and PD-1 Antibody Combination With Anlotinib in HER2-low, Unresectable and/or Metastatic Breast Cancer

Guangdong Provincial People's Hospital0 sites40 target enrollmentSeptember 1, 2024

ConditionsBreast Cancer

InterventionsTucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib

DrugsTucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib

Overview

Phase: Phase 2
Intervention: Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
Conditions: Breast Cancer
Sponsor: Guangdong Provincial People's Hospital
Enrollment: 40
Primary Endpoint: Progression-free survival(PFS)
Status: Not yet recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer.

Participants must have HER2-low and PD-L1 positive （CPS≥1）breast cancer that has been treated before.

Participants' cancer:

Cannot be removed by an operation Has spread to other parts of the body

Registry

clinicaltrials.gov

Start Date

September 1, 2024

End Date

December 31, 2026

Last Updated

last year

Study Type

Interventional

Study Design

Single Group

Sex

Female

Investigators

Sponsor

Guangdong Provincial People's Hospital

Responsible Party

Principal Investigator

Kun Wang

Professor

Guangdong Provincial People's Hospital

Eligibility Criteria

Inclusion Criteria

•Has pathologically documented breast cancer that:
•Is unresectable or metastatic
•Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
•Is HR-positive
•Has progressed on, and would no longer benefit from, endocrine therapy
•Has been treated with 0 to 1 prior lines of chemotherapy in the recurrent or metastatic setting
•Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists \[ASCO-CAP\] guidelines)
•PD-L1 positive （CPS≥1）
•Has documented radiologic progression (during or after most recent treatment)
•Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:

Exclusion Criteria

•Allergies to any monoclonal antibody or tucidinostat preparation have been known, and hypersensitivity reactions of more than 3 levels have occurred
•Previously received histone deacetylase inhibitors,or immune checkpoint inhibitor, or angiogenesis inhibitors.
•Subjects with any active, known or suspected autoimmune disease or history of autoimmune disease.
•Known active CNS metastases and/or carcinomatous meningitis.
•Received a live vaccine within 4 weeks of the first dose of study medication.
•Major surgery received or severe traumatic injury, fracture, or ulcer occurred within 4 weeks of the first dose of study medication.
•Pregnant or lactating female.
•Uncontrolled clinically significant systemic diseases, including active infection, unstable angina, angina occurred within 3 months,≥ NYHA II congestive heart failure, myocardial infarction occurred within 6 months, severe arrhythmia, liver, kidney, or metabolic disease.
•Participate in other clinical trials currently or within 4 weeks prior to enrollment.